![Pharmaceutical industry / Pharmacy / Pharmaceuticals policy / Biotechnology / Immunogenicity / Immunology / European Federation of Pharmaceutical Industries and Associations / Biopharmaceutical / Novartis / Sanofi / Pharmaceutical drug / Drug development Pharmaceutical industry / Pharmacy / Pharmaceuticals policy / Biotechnology / Immunogenicity / Immunology / European Federation of Pharmaceutical Industries and Associations / Biopharmaceutical / Novartis / Sanofi / Pharmaceutical drug / Drug development](https://www.pdfsearch.io/img/980042c982b966cee3102e7d6f615f7b.jpg) Date: 2012-11-23 07:10:19Pharmaceutical industry Pharmacy Pharmaceuticals policy Biotechnology Immunogenicity Immunology European Federation of Pharmaceutical Industries and Associations Biopharmaceutical Novartis Sanofi Pharmaceutical drug Drug development | | ABIRISK Making novel drugs safer for patients A growing number of medicines are based on biological molecules such as proteins and monoclonal antibodies. These novel drugs have resulted in new, more effective treatments Add to Reading ListSource URL: www.abirisk.euDownload Document from Source Website File Size: 124,66 KBShare Document on Facebook
|